ARUP LABORATORIES | aruplab.com
500 Chipeta Way, Salt Lake City, Utah 84108-1221
phone: 801-583-2787, toll free: 800-522-2787
Tracy I. George, MD, Chief Medical Officer

Patient Report

Patient Age/Gender: Unknown

Specimen Collected: 25-Jun-21 09:34

JAK2 V617F Qual w/Rflx to JAK2 Exon 12 | **Received: 25-Jun-21 09:49** | **Report/Verified: 25-Jun-21 10:21**

Procedure	Result	Units	Reference Interval
JAK2 QUAL,Source	Not Specified		
JAK2 QUAL Mutation by PCR	Detected [f1 i1]		

Result Footnote

f1: JAK2 QUAL Mutation by PCR

There is evidence of the JAK2 V617F mutation by ddPCR analysis.

This result has been reviewed and approved by Peng Li, M.D.

Test Information

i1: JAK2 QUAL Mutation by PCR

INTERPRETIVE INFORMATION: JAK2 (V617F) Mutation by ddPCR, Qualitative

This assay is designed to detect the point mutation c.1849G>T (V617F) of the JAK2 gene. JAK2 V617F mutations are present in patients with myeloproliferative neoplasms.

Methodology: DNA from whole blood or bone marrow specimens is amplified in an allele-specific droplet digital PCR (ddPCR) multiplex reaction targeting the JAK2 c.1849G>T single nucleotide mutation encoding the V617F mutation. The limit of detection for this assay is 0.5 percent mutated alleles.

Limitations: Variants in genes other than JAK2 are not detected. Variant alleles of JAK2 other than V617F (c.1849G>T) are not reported. Samples with JAK2 V617F mutations below the limit of reporting may not be detected.

Results of this test must always be interpreted in the context of morphologic and other relevant data, and should not be used alone for a diagnosis of malignancy.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.